Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study

In Press, (this is not the final "Version of Record"). Available online 29 May, 2024
Author(s): Xiaohui Cai, Jing Zhao and Yalong Dang*
Published on: 29 May, 2024

DOI: 10.2174/0115748871315894240514044305

Price: $95

Abstract

Objective: This study aimed to assess the efficacy and safety of anti-VEGF combined with dexamethasone implant for the retinal vein occlusion patients with macular edema.

Methods: In this prospective, case-controlled, cohort clinical trial (Register ID: ChiCTR2400080048), patients with non-ischemic retinal vein occlusion were enrolled from the Sanmenxia Central Hospital from August 2020 to April 2023. The patients were randomized into two groups. All the patients received ranibizumab intravitreal injection in the first 3 consecutive months. For the ranibizumab group, anti-VEGF injections were as needed thereafter in case of recurrence of macular edema; For the combination group, the patients received an intravitreal dexamethasone implant injection at 15 days after the first ranibizumab injection. The primary outcome measurements were improvement in best corrected visual acuity (BCVA) and reduction in central macular thickness (CMT). The secondary outcomes were recurrence of macular edema, number of intravitreal injections, and injection interval. Safety profiles were also recorded.

Results: A total of 124 patients were included, of which 73 patients completed all follow-ups. Both the ranibizumab monotherapy and the combination therapy significantly improved BCVA at all time points, compared to the baseline. The combined group achieved more BCVA improvement in 3 months, 6 months, and 12 months, compared to the ranibizumab alone group. Compared to the baseline, both groups achieved significant reductions in CMT at all follow-ups. However, the combination group showed more CMT reduction at 1 week post injection, compared to the ranibizumab group. The combination group had a significantly longer injection interval, lower injection time, and recurrence of macular edema. Ocular hypertension was the most common adverse events. Lastly, intraocular pressure was all well controlled by 1-3 glaucoma medications without surgical intervention.

Conclusion: The combination therapy could significantly improve the BCVA and reduce the CMT with a good safety profile.

[1]
Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye 2011; 25(8): 981-8.
[http://dx.doi.org/10.1038/eye.2011.92] [PMID: 21546916]
[2]
Iftikhar M, Mir TA, Hafiz G, et al. Loss of peak vision in retinal vein occlusion patients treated for macular edema. Am J Ophthalmol 2019; 205: 17-26.
[http://dx.doi.org/10.1016/j.ajo.2019.03.029] [PMID: 30954469]
[3]
Tang Y, Cheng Y, Wang S, Wang Y, Liu P, Wu H. The development of risk factors and cytokines in retinal vein occlusion. Front Med 2022; 9: 910600.
[http://dx.doi.org/10.3389/fmed.2022.910600] [PMID: 35783660]
[4]
Ashraf M, Souka A A R, Singh RP. Central retinal vein occlusion: Modifying current treatment protocols. Eye 2016; 30(4): 505-14.
[http://dx.doi.org/10.1038/eye.2016.10] [PMID: 26869163]
[5]
Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127(9): 1101-14.
[http://dx.doi.org/10.1001/archophthalmol.2009.234] [PMID: 19752419]
[6]
Feng X, Li Y, Wu M, et al. Efficacy of subthreshold micropulse laser photocoagulation therapy versus anti-vascular endothelial growth factor therapy for refractory macular edema secondary to non-ischemic branch retinal vein occlusion. J Int Med Res 2023; 51(8): 03000605231194462.
[http://dx.doi.org/10.1177/03000605231194462] [PMID: 37652453]
[7]
Kumagai K, Ogino N, Fukami M, Furukawa M. Vitrectomy for macular edema due to retinal vein occlusion. Clin Ophthalmol 2019; 13: 969-84.
[http://dx.doi.org/10.2147/OPTH.S203212] [PMID: 31354231]
[8]
Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica 2019; 242(3): 123-62.
[http://dx.doi.org/10.1159/000502041] [PMID: 31412332]
[9]
Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye 2013; 27(7): 787-94.
[http://dx.doi.org/10.1038/eye.2013.107] [PMID: 23722722]
[10]
Tah V, Orlans HO, Hyer J, et al. Anti-VEGF therapy and the retina: An update. J Ophthalmol 2015; 2015: 1-13.
[http://dx.doi.org/10.1155/2015/627674] [PMID: 26417453]
[11]
How It Works Available from: https://www.ozurdex.com/howitworks
[12]
Chin EK, Almeida DRP, Velez G, et al. Ocular hypertension after intravitreal dexamethasone (Ozurdex) sustained-release implant. Retina 2017; 37(7): 1345-51.
[http://dx.doi.org/10.1097/IAE.0000000000001364] [PMID: 27806001]
[13]
Shibi Dev BN, Sweta VD, Sandhya R. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study. Indian J Ophthalmol 2022; 70(2): 585-9.
[http://dx.doi.org/10.4103/ijo.IJO_684_21] [PMID: 35086242]
[14]
Albuainain A, Al Jindan M, Al Bloushi B. Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (Ozurdex) and implant one-piece posterior capsule intraocular lens. Saudi J Ophthalmol 2020; 34(2): 145-7.
[http://dx.doi.org/10.4103/1319-4534.305044] [PMID: 33575542]
[15]
Cai X, Zhao J, Dang Y. Combination therapy with Anti-VEGF and intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion. Curr Eye Res 2024; 1-7.
[http://dx.doi.org/10.1080/02713683.2024.2343055] [PMID: 38639040]
[16]
Gu X, Yu X, Song S, Dai H. Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese Population. Ophthalmic Res 2017; 58(1): 8-14.
[http://dx.doi.org/10.1159/000458534] [PMID: 28334720]
[17]
Du X, Sheng Y, Shi Y, Du M, Guo Y, Li S. The efficacy of simultaneous injection of dexamethasone implant and ranibizumab into vitreous cavity on macular edema secondary to central retinal vein occlusion. Front Pharmacol 2022; 13: 842805.
[http://dx.doi.org/10.3389/fphar.2022.842805] [PMID: 35300292]
[18]
Ren F, Gong H, Zhang H, et al. Evaluating the one-year efficacy of combined Anti-VEGF and dexamethasone implant treatment for macular edema in retinal vein occlusions. Med Sci Monit 2023; 29: e939277.
[PMID: 37301978]
[19]
Gao L, Zhou L, Tian C, et al. Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: A meta-analysis. BMC Ophthalmol 2019; 19(1): 8.
[http://dx.doi.org/10.1186/s12886-018-1016-7] [PMID: 30621640]
[20]
Zhang M, Liu Y, Song M, et al. Intravitreal dexamethasone implant has better retinal perfusion than anti-vascular endothelial growth factor treatment for macular edema secondary to retinal vein occlusion: A five-year real-world study. Ophthalmic Res 2023; 66(1): 247-58.
[http://dx.doi.org/10.1159/000527447] [PMID: 36215955]
[21]
Liang X, Shen B, Ou Z, An H, Li L. Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion. Front Med 2022; 9: 930508.
[http://dx.doi.org/10.3389/fmed.2022.930508] [PMID: 36172537]
[22]
Coscas G, Augustin A, Bandello F, et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 2014; 24(1): 1-9.
[http://dx.doi.org/10.5301/ejo.5000376] [PMID: 24249150]
[23]
Querques L, Querques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 2013; 229(1): 21-5.
[http://dx.doi.org/10.1159/000342160] [PMID: 23006995]
[24]
Ye Y, Huang Z, Wu Q-W, Hui Y-N, Song Y-P, Song YP. Long-term outcomes of anti-VEGF treatment with 5+PRN regimen for macular edema due to central retinal vein occlusion. Int J Ophthalmol 2023; 16(10): 1642-50.
[http://dx.doi.org/10.18240/ijo.2023.10.13] [PMID: 37854371]
[25]
Kishore K, Bhat PV, Venkatesh P, Canizela CC. Dexamethasone intravitreal implant for the treatment of macular edema and uveitis: A comprehensive narrative review. Clin Ophthalmol 2022; 16: 1019-45.
[http://dx.doi.org/10.2147/OPTH.S209395] [PMID: 35418744]
[26]
Simsek M, Citirik M, Ozates S, Ozkoyuncu D. The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario. Indian J Ophthalmol 2018; 66(6): 831-6.
[http://dx.doi.org/10.4103/ijo.IJO_1259_17] [PMID: 29785994]
[27]
Chang-Lin JE, Burke JA, Peng Q, et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011; 52(7): 4605-9.
[http://dx.doi.org/10.1167/iovs.10-6387] [PMID: 21421864]
[28]
Xu S, Song Z, Li G, Zhang C. Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: A systematic review and meta-analysis. BMJ Open Ophthalmol 2022; 7(1): e001086.
[http://dx.doi.org/10.1136/bmjophth-2022-001086]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy